The Innovative Biological Valve is Rapidly Adopted Thanks to
Excellent Haemodynamic Performance, High Biocompatibility and an Easy
Implant Procedure
During the 5th EACTS/ESTS joint Meeting, held on September 10-13
in Stockholm Sorin Group (MIL:SRN), Europe's largest medical
technology company specialized in the treatment of cardiovascular
diseases and leader in Cardiac Surgery, organised its second
Investigator Meeting on "Solo Valve Trial", the European Multicentric
Clinical study on Freedom Solo(TM) aortic bioprosthesis.
Preliminary ad interim analysis data have confirmed the excellent
performances of this product in terms of haemodynamics, recovery of
left ventricle systolic function, low early and late complication
associated with friendly implant technique. These unique clinical
features of Freedom Solo(TM) have been positively commented by
different investigators and users in occasion of the Congress.
"Freedom Solo(TM) represented an innovation in the heart valve
prosthesis arena, due to its unique characteristics of being a totally
biological valve, virtually identical to the native valve, which can
be easily and quickly implanted with a single suture line, giving
superior results in terms of haemodynamics. Since its first launch in
the market in late 2004, we have implanted almost 150 units at our
institution with excellent results", said Dr. Beholz (Charite
Hospital, Berlin, Germany).
"Our patients need three new aortic leaflets only to replace their
native diseased leaflets. In clinical practice Freedom Solo(TM) allows
most of the patients to avoid conventional prosthesis with polyester
materials. This results in better haemodynamic performances and an
improved patient well-being", said Dr. Repossini (Istituto Clinico
Humanitas-Gavazzeni, Bergamo, Italy), the first worldwide implanter of
Freedom Solo in 2004.
This aortic valve has no rigid support that other biological
valves have, so called stented valves, in order to secure them to the
appropriate position. Such design allow Freedom Solo(TM) to have a
better haemodynamic performance without making the implant procedure
more complex, since a single suture line only is required.
Freedom Solo(TM) is considered an easy to implant valve, with very
high haemodynamic characteristics: "I was not a believer in stentless
valves: I did not understand the need of a difficult and long-term
implant technique in order to reach only slightly better haemodynamic
results than with stented models. I am now implanting Freedom Solo(TM)
because, with this valve which is totally biological and suitable to
be implanted in a supra-annular position, I can obtain superior
haemodynamic performances with a fast and simple implant technique,
thus reaching the most benefit for my patients", said Prof Kemkes,
(Bogenhousen Hospital, Munich, Germany).
Thanks to its recent implant of Freedom Solo(TM), the Zwolle
hospital centre in The Netherlands is the 100th user centre of Freedom
Solo in Europe.
This device represents a real break-through in the growing segment
of biological heart valve prostheses, confirming Sorin Group's strong
commitment to product innovation and new therapies. "Freedom Solo(TM)
is the result of more than 25 years of Sorin Group in house expertise
in the harvesting and treatment of biological tissues and
manufacturing of high performance bioprostheses", said Franco Vallana,
President of the Cardiac Surgery Business Unit.
About Freedom Solo aortic bioprosthesis
-- Unique totally biological pericardial valve
-- Innovative design which allow a fast and easy single suture
implant technique
-- 100% tissue to annulus ratio thanks to its supra-annular
positioning
-- Ready to implant thanks to the exclusive detoxification
treatment which eliminates the need for rinsing
Sorin Group
The Sorin Group (Reuters code: SORN.MI), a world leader in the
development of medical technologies for cardiac surgery, offers
innovative therapies for cardiac rhythm dysfunctions, interventional
cardiology and the treatment of chronic kidney diseases. The companies
of the Sorin Group are: Dideco, CarboMedics, COBE Cardiovascular,
Stockert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Soludia.
The Sorin Group has more than 4,600 employees working at facilities in
more than 80 countries throughout the world to serve over 5,000 public
and private treatment centers.
www.sorin.com
